Connecta Therapeutics

Executive Summary

Connecta Therapeutics is a private Spanish biotechnology company headquartered in Barcelona, focused on discovering and developing innovative small-molecule therapies for central nervous system (CNS) disorders. Founded in 2019, the company aims to meaningfully improve the lives of patients suffering from conditions such as Fragile X Syndrome (FXS), where its lead asset, CTH120, recently completed a Phase 1 clinical trial (NCT06480968) in June 2023 to November 2024. The trial evaluated safety and tolerability in healthy volunteers and FXS patients, marking an important milestone for the company. As an early-stage player with a single disclosed pipeline candidate, Connecta operates in a high-risk, high-reward space within CNS drug development, where successful treatments remain scarce. The company's progress hinges on advancing CTH120 into Phase 2 trials and demonstrating proof-of-concept, as well as securing additional funding or partnerships to support its pipeline. With a focused strategy and a completed Phase 1 trial, Connecta is positioned to move toward later-stage development, though the lack of disclosed financial details and additional pipeline assets tempers near-term visibility.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2 trial for CTH120 in Fragile X Syndrome60% success
• Q2 2026Presentation of Phase 1 safety and pharmacokinetic data at a scientific conference80% success
• Q3 2026New partnership or financing agreement to support pipeline expansion40% success